Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells

By Fechner G.   Perabo F.G.E.   Schmidt D.H.   Haase L.   Ludwig E.   Schueller H.   Blatter J.   Mller S.C.   Albers P.  

Urology, Vol. 61, Iss. 2, 2003-02 ,pp. : 468-473

Elsevier

Access to resources Recommend Favorite

Frequency and characterization of p53 mutations in clinically localized prostate cancer

By Hall M.C.   Navone N.M.   Troncoso P.   Pollack A.   Zagars G.K.   von Eschenbach A.C.   Conti C.J.   Chung L.W.K.  

Urology, Vol. 45, Iss. 3, 1995-03 ,pp. : 470-475

Elsevier

Access to resources Recommend Favorite

Tumour Grade, Proliferation, Apoptosis, Microvessel Density, p53, and bcl-2 in Prostate Cancers: Differences Between Tumours Located in the Transition Zone and in the Peripheral Zone

By Erbersdobler A.   Fritz H.   Schnoger S.   Graefen M.   Hammerer P.   Huland H.   Henke R.-P.  

European Urology, Vol. 41, Iss. 1, 2002-01 ,pp. : 40-46

Elsevier

Access to resources Recommend Favorite

Dual 5 -reductase inhibitor, dutasteride, inhibits androgen action, cell growth/viability in prostate cancer cell lines

By Lazier C.   Thomas L.   Douglas R.   Schmidt L.   Tindall D.  

European Urology Supplements, Vol. 2, Iss. 1, 2003-02 ,pp. : 37-37

Elsevier

Access to resources Recommend Favorite

p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy

By Huang A.   Gandour-Edwards R.   Rosenthal S.A.   Siders D.B.   Deitch A.D.   Devere White R.W.  

Urology, Vol. 51, Iss. 2, 1998-02 ,pp. : 346-351

Elsevier

Access to resources Recommend Favorite